# A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

> clinical trial · VERIFIED · 2026-06-22

Status: RECRUITING · Sponsor: BeOne Medicines · Condition: Chronic Lymphocytic Leukemia

- Company: BeOne Medicines
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06970743

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.